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1. Introduction
A classical model that describes blood coagulation
asamulti-stepseriesofeventswasdevelopednearly40
years ago [1,2]and, while being constantly reﬁned and
ameliorated, has remained mostly valid to date. The
current model of this “coagulation cascade” describes
two distinct pathways, both eventually leading to the
activation of prothrombin to thrombin which in turn is
responsible for ﬁbrin formation. The intrinsic pathway
is initiated by the activation of Factor XII to Factor
XIIa, the enzymeformof the zymogenFactor XII. The
extrinsic pathway, considered the physiologic initiator
of bloodcoagulation,is triggered by the formationof a
complex that includes Factor VIIa, tissue factor, phos-
pholipid membranes and calcium ions. Anionic phos-
pholipids, mainly phosphatidylserine,are critical com-
ponents of this complex and it is commonly accepted
that activated platelets, in the absence of primary in
vivo data, accumulate at the site of tissue injury and
provide most of these negatively charged species. The
activation of this pathway catalyzes the conversion of
Factor IX and Factor X to Factor IXa and Factor Xa,
respectively [3].
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coness Medical Center, 330 Brookline Ave., Boston MA 02115,
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Tissue factor is an integral membrane protein with a
molecularweightof47,000constitutivelyexpressedby
non vascular cells, and therefore extrinsic to blood [4].
According to the accepted model, a small amount of
Factor VII circulates in its active form as Factor VIIa
but is kept physically segregated from tissue factor by
the integrity of the endothelium and has no signiﬁcant
biologic activity. Upon vascular damage Factor VIIa
comes in contact with tissue factor expressed by the
underlying non-vascular tissues when these tissues are
exposed to ﬂowing blood, and Factor IXa and Factor
Xaaregenerated. Thismodelpredictsthattissuefactor
is not constitutively synthesized by cells normally in
contact with the blood stream, lest intravascular coag-
ulation ensues. However, endothelial cells and mono-
cytes can synthesize tissue factor upon activation [5,
6]. Agonists classically recognized to cause synthe-
sis of tissue factor by endothelial cells and/or mono-
cytes include bacter bacterial endotoxin (lipopolysac-
charide, LPS), Interleukin-1 (IL-1), Tumor Necrosis
Factor-α (TNF-α), immune complexes, platelets and
platelet membranes. However, the list is constantly
growing [7–9]. Whether other types of white cells be-
side the monocyte synthesize and express tissue factor
upon activation is still a matter of debate [8,10–13].
It must be emphasized that tissue factor expression by
leukocytes and endothelial cells involves de novo pro-
tein synthesis and requires several hours. Monocyte
and endothelial cell-derived tissue factor is therefore
unlikely to be involved in triggering blood coagulation
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upon tissue injury but rather has been mostly linked
to wound repair and remodeling, thrombus formation
and atherosclerosis [14]. Finally, tissue factor has also
been demonstrated in plasma in minute concentrations
ofabout100–150ng/ml[15–17]. Thephysiologicrele-
vanceofcirculatingtissuefactorhasremainedobscure.
Over the past several years, experimental data have
been obtained that do not ﬁt this classical model. In
1984 we [18] and others [19] independently discov-
ered a protein expressed on the platelet surface only
upon activation. The protein was eventually shown
to be a vascular cell adhesion molecule that mediated
leukocyte-platelet and endothelial cell-platelet inter-
action, and was renamed P-selectin [20]. The pres-
enceofP-selectinwas alsodemonstratedinendothelial
cells [21,22]. While the ﬁrst evidence that P-selectin
wasindeedanadhesionmoleculewasobtainedinvitro,
the function of the protein was subsequently investi-
gatedin an animal model[23]. An artero-venousshunt
implantedinababoon(PapioCynocephalus)was ﬁtted
with a Dacron graft. Under the experimental condi-
tionsusedthegraftishighlythrombogenicandathrom-
bus formed rapidly. When autologous radiolabelled
leukocytes were injected they rapidly accumulated in
the graft, as expected. Antibodies to P-selectin inhib-
ited leukocyte accumulation, thus conﬁrming the role
of P-selectin as a platelet-leukocyteadhesion molecule
in an in vivo animal model. However, it was also ob-
served that beside inhibiting leukocyte accumulation,
antibodies to P-selectin were also able to inhibit ﬁbrin
deposition within the grafts. This observation was to-
tally unexpected and could not be explained based on
thecurrentknowledgeofbloodcoagulationthatdidnot
proposearoleforP-selectin. Whilemonocyteaccumu-
lation was likely inhibited by P-selectin blockade, this
could not account for ﬁbrin inhibition since these cells
shouldnotrepresentasigniﬁcantsourceoftissuefactor
in the short time frame, measured in minutes, of our
model. This work documented a P-selectin-dependent
pathwayofbloodcoagulationanddemonstratedforthe
ﬁrst time a link between P-selectin and ﬁbrin forma-
tion, but the molecular basis of this observation was
obscure.
To investigate the possible role of P-selectin in ﬁb-
rin formation, we tested the hypothesis that binding of
monocytestoP-selectinexpressedbyactivatedplatelets
within the thrombus upregulates tissue factor activity.
Platelets and platelet membranes had long been in-
cluded in the list of agonists capable of monocyte ac-
tivation. Freshly isolated peripheral blood monocytes
cultured in the presence of soluble P-selectin or coin-
cubatedwithChinesehamsterovary(CHO)cells trans-
fected with the cDNA for P-selectin expressed proco-
agulant activity (as assessed by a clotting assay), tis-
suefactorantigen(asassessedbyimmunoﬂuorescence)
and tissue factor mRNA (as assessed by semiquanti-
tative RT-PCR). The effect was inhibited by a mono-
clonal antibody to P-selectin [24]. This was the ﬁrst
demonstrationthat P-selectin, beside its role as a dock-
ing molecule important for the initial steps of the in-
ﬂammatory response, had also a signaling function in-
volvedintheactivationofbloodcoagulation. However,
tissue factor expression by P-selectin-activated mono-
cytes required protein synthesis and the time scale of
ﬁbrin formation could not explain the results obtained
in the baboon model.
In experimentsaimed at investigatingthe role of cir-
culating tissue factor in blood coagulation, Giesen and
coworkers employed an in vitro system in which col-
lagen coated glass slides or pig arterial media were
exposed to ﬂowing human blood in a perfusion par-
allel ﬂow chamber [12]. While neither surface con-
tained human tissue factor at the beginning of the ex-
periment,microscopicanalysisofthethrombusshowed
the formationof tissue factor-richmicrothrombiafter a
5 minute perfusion with blood directly ﬂowing from a
normal volunteer’s vein. The appearance of tissue fac-
tor was well beforeany de novo synthesis of tissue fac-
tor by monocytes might occur. Although tissue factor-
containing leukocytes were detected by immunostain-
ing, much of the protein appeared to be extracellular.
Underthe experimentalconditionsdescribed,the ﬂow-
ing blood is the only possible source of tissue factor.
These observations led the authors to conclude that
blood-borne TF is functionally active and potentially
thrombogenic.
Inordertogainabetterunderstandingofthecomplex
molecular mechanisms of blood coagulation in vivo,
we have recently developed an intravital microscopy
system for real-time imaging of thrombus formation in
mice. The system has been described in detail else-
where [25,26]. Brieﬂy, the cremaster muscle of a liv-
ingmouse is exteriorizedandpinnedacross a coverslip
mountedon a custom-designedtray. This allows direct
visualization of the microcirculation of the living ani-
mal. Thepreparationisthenplacedonthestageofaﬂu-
orescence microscope that includes both wideﬁeld and
confocal capabilities. To induce thrombus formation,
laser pulses, focused through the microscope lenses,
injure the vascular wall of either arterioles or venules.
Fluorescentlylabeled cells, or antibodies to circulating
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jugular vein to visualize single thrombus components.
Data from up to three different ﬂuorescent channels
plus brightﬁeld can be digitally recorded for off-line
analysis. The confocal component of the microscope
employs Nipkow disk technology (as opposed to the
point scanning technique used by traditional confocal
microscopes) to collect images at video frame rates.
We took advantage of this instrumentation to re-
visit the role of P-selectin in ﬁbrin deposition. Ge-
netically engineered mice lacking the leukocyte recep-
tor for P-selectin, P-Selectin Glycoprotein Ligand-1
(PSGL-1), have been generated in our laboratory [27].
By injecting ﬂuorescently labeled antibodies to ﬁbrin
we were able to demonstrate that ﬁbrin deposition in
PSGL-1−/− mice is impaired compared to wild type
mice. SimilarresultswereobtainedwithP-selectin−/−
mice and in wild-type mice treated with blocking an-
tibodies to P-selectin [28]. These results conﬁrm and
extend those obtained in the baboon model over a
decade earlier and again support the existence of a P-
selectin/PSGL-1-dependent pathway of blood coagu-
lation. To investigate whether this pathway involves
tissuefactor,ﬂuorescentlylabeledanti-tissuefactoran-
tibodies were also injected to detect tissue factor in
the developing thrombus. Tissue factor antigen accu-
mulated at the thrombus/vessel wall interface as well
as within the developing thrombus [28]. Tissue factor
accumulation in the thrombus was indeed impaired in
PSGL-1−/− and P-selectin−/− mice. These data in-
dicate that the P-selectin/PSGL-1 receptor pair is re-
quired for tissue factor accumulation at sites of vessel
wall injury.
It has been known for over ﬁfteen years that many
eukaryotic cells release vesicles either spontaneously
or upon stimulation. Some of these vesicles originate
directly from the cell membrane and have been given
different names, including ectosomes [29], microvesi-
cles [30], and micoparticles [31]. Platelets, for ex-
ample, express microparticles upon stimulation [32];
these microparticles can be detected in the periph-
eral blood by ﬂow cytometry and their number corre-
lates with the extent of platelet activation [31]. An
incomplete list of biological functions of microparti-
cles reported in vitro includes the presence of bind-
ing sites for Factor VIII in platelet-derived microparti-
cles [33], upregulation of endothelial cell synthesis of
proinﬂammatory cytokines by neutrophil-derived mi-
croparticles [34], transfer of the chemokine receptor
CCR5 from monocytes to cells not expressing it, thus
allowing HIV infection of the latter [35]. More rele-
vantto the purposeof this review,the formationof pro-
coagulant microparticles by monocytes has also been
demonstrated[36]. Monocytes exposed to LPS release
prothrombinaseactivity in thesupernatantthat is likely
attributable to phosphatidylserine-expressing vesicles.
This was conﬁrmed by ﬂow cytometry, probing the
cell-freesupernatantofLPSstimulatedmonocyteswith
ﬂuorescein-labeled annexin V. In addition, these mi-
croparticlesexpresstissuefactoractivity,asassessedby
a Factor Xa generation assay. Finally, ﬂow cytometry
also shows that antibodies directed against several cell
surface antigens, including CD14, CD11a, and CD18,
bind to microparticles. Taken together these results
indicate that upon LPS stimulation, monocytes shed
microparticles that are potentially responsible for the
dissemination of procoagulantactivity;these micropar-
ticles also express at least some of the integral mem-
brane proteins expressed by intact monocytes. While
one might be tempted to consider microparticles as in
vitro artifacts or, possibly, cell debris devoid of func-
tionalsigniﬁcanceinvivo, severalauthorshavedemon-
stratedincreasednumbersofmicroparticlesoriginating
from cells of different lineage in a variety of diseases
suggesting that their formation is a regulated process
with physiologic implications [37–44].
We have analyzed freshly isolated cell-free plasma
from normal volunteers for the presence of mi-
croparticles bearing both tissue factor and PSGL-1.
Polystyrene beads coated with anti-tissue factor anti-
bodies were incubated with cell-free plasma to cap-
ture tissue factor-bearing microparticles. The beads
werethensedimentedbycentrifugation,incubatedwith
ﬂuorescein labeled anti PSGL-1 antibodies and ana-
lyzedby ﬂow-cytometry[28]. By this methodwe were
able to demonstrate the presence in unstimulated hu-
man blood of circulating microparticles that are cap-
turedbyanti-tissuefactorantibodiesandstainwithanti
PSGL-1 antibodies, and therefore must express both
antigens. Using the parallel ﬂow chamber described
above, transfer of tissue factor-bearing microparticles
from leukocytes to platelets adherent to the collagen
coated slide has been suggested based on immunoelec-
tronmicroscopy[45]. Colocalizationontheseparticles
of tissue factor and CD15, a carbohydrate moiety that
is a component of numerous leukocyte membrane pro-
teins including PSGL-1, and is part of the recognition
site of this protein for P-selectin [46], was observed.
This tissue factor-initiated P-selectin/PSGL-1-
mediated blood coagulation pathway appears to play a
role in thrombogenesis. This pathway is distinct from
the classical pathwayin which extrinsic tissue factor in
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and thus initiates blood coagulation directly. In this
second pathway, monocytes, constitutively expressing
PSGL-1, are activated by as yet unknown agonists in
vivotosynthesizeandexpresstissue factorontheirsur-
face. The same agonists or other molecules then signal
the cells to shed microparticles expressing both tissue
factor and PSGL-1 on their surface. These microparti-
cles circulate at a relatively low concentration, and tis-
suefactoriseitherinactiveortoodilutetoinitiateblood
coagulation. Upon vessel wall injury, platelets accu-
mulate. Upon their activation, they express P-selectin.
ThecirculatingPSGL-1-bearingmicroparticlesbindto
the boundactivatedplatelets, deliveringtissue factorto
the developing platelet thrombus. Activated platelets
onthesurfaceoftheDacronshuntoratthesiteoflaser-
induced vessel wall injury capture tissue factor [23,
28]. Once concentrated within the thrombus, tissue
factor reaches a critical concentration and triggers the
initiation of blood coagulation.
Whilethepresenceandfunctionalsigniﬁcanceofcir-
culating tissue factor is gaining attention, tissue factor
constitutivelyexpressedbynon-vascularcellsisclearly
important for normal hemostasis. With the availabil-
ity of the intravascular microscopy system described
above, we set out to compare the role of both extrin-
sic and blood-borne tissue factor in blood coagula-
tion. Genetically engineered mice expressing very low
level of TF (approximately1% comparedto wild type)
have been generated. These “low TF” mice, unlike
TF−/− mice that die during embryonic development,
show normal growth and development [47]. We trans-
planted bone marrow obtained from low TF mice into
wild type mice and bone marrow from wild type mice
into low TF mice. This approach allowed us to distin-
guishtherelativecontributionoftissuefactorgenerated
by hematopoietic cells from that of non-hematopoietic
cell-derivedtissuefactor. Platelet, ﬁbrinandtissue fac-
tor accumulation within the thrombus were analyzed
in real time upon laser induced tissue injury. Low TF
mice generated platelet thrombi that were markedly
reduced in size and that lacked both tissue and ﬁb-
rin. These results indicate an important role for tis-
sue factor-initiated thrombin generation in platelet ac-
tivation. Chimeric mice expressing normal vessel wall
tissue factor but minimal hematopoietic cell-derived
tissue factor displayed a modest reduction in platelet
thrombus size but markedly impaired tissue factor and
ﬁbrin deposition within the thrombus. On the contrary,
laser-induced vessel injury in chimeric mice express-
ing normal bone marrow-derived tissue factor but low
vessel wall tissue factor yielded a modest reduction in
platelet thrombus size but had normal tissue factor and
ﬁbrin content [48]. These data allowed us to conclude
that hematopoieticand tissue derived tissue factor play
distinctrolesinbloodcoagulationandthrombogenesis.
Extrinsic tissue factor acts rapidly upon tissue injury
to generate thrombin that activates platelets adherent
to the vessel wall;presumably these platelets release
ADP,whichinturnsactivatesotherplatelets, leadingto
the formation and rapid growth of a platelet thrombus.
Tissue factor derived from hematopoietic cells, blood
bornetissuefactor,thenleadstothegenerationofﬁbrin
within the growing thrombus. Since we have shown
that this phenomenon requires P-selectin/PSGL-1 in-
teraction, we maintain that blood borne tissue factor is
associated with PSGL-1-bearing microparticles.
Theagonist(s)thatsignalleukocytestoexpresstissue
factorandshedtissuefactor/PSGL-1bearingmicropar-
ticles have not been identiﬁed. Andre and cowork-
ers have engineered a mouse strain that expresses a
truncated form of P-selectin lacking the cytoplasmic
tail [49]. These mice have an approximately three-
fold increase in the concentration of circulating sol-
uble P-selectin which results in a procoagulant state.
Thesemicehavea higherlevel ofcirculatingmicropar-
ticles expressing tissue factor. These microparticles
also express the integrin αMβ2 (Mac-1), suggesting
their leukocytic origin. Furthermore,incubation of hu-
man blood with a P-selectin-Ig chimera shortens the
whole blood clotting time whereas mice deﬁcient in
PSGL-1 have lower numbers of microparticles than
wild type mice [50]. It would appear that P-selectin
maybeinvolvedinthegenerationoftissuefactor-bear-
ing microparticles by leukocytes but the presence of
microparticlesin PSGL-1 null and P-selectin null mice
indicates that multiple mechanisms beside P-selectin
and PSGL-1 are important in microparticlegeneration.
Many questions remain to be answered. Firstly, the
methods used to quantitate microparticles and associ-
ated antigens in blood or platelet-poor plasma by our-
selves and others are inadequate. These measurements
are based upon light scattering during ﬂow cytometry,
andlightscatteringofsmall particlesis non-linearwith
regard to particle size and inaccurate. Microparticles,
cellular debris and instrument noise are not easily sep-
arated by ﬂow cytometry. Furthermore, formal quan-
titation of tissue factor antigen on microparticles, and
not simply microparticle concentration, is important
sincemostmicroparticlesinbloodarenotderivedfrom
leukocytes and may have little or nothing to do with
thrombogenesis. Second, the functional state of tis-
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unknown since efforts are usually directed to assaying
tissue factor antigen. Is blood-bornetissue factor func-
tionally active? What are the signals and the molecular
basis for its tissue factor activation? Third, are there
proteins uniquely expressed on the microparticle that
are not expressed on the parent cell fromwhich the mi-
croparticle is derived? Fourth, what is the mechanism
of microparticle generation and what is the fate of cir-
culatingmicroparticles? Withourdemonstrationofthe
incorporation of leukocyte-derived microparticles into
the developing thrombus in an interaction mediated by
P-selectinandPSGL-1,weprovidetheﬁrstinsightinto
a physiologic role for microparticles in their contribu-
tion to the development of ﬁbrin during thrombus for-
mation in a living animal. Further developments in the
technology of microparticle analysis and their applica-
tion to study of tissue factor initiation of blood coagu-
lation should prove fruitful in future investigations.
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